The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

Jun. 05, 2020
Applicant:

Janssen Vaccines & Prevention B.v., Leiden, NL;

Inventors:

Boerries Brandenburg, Utrecht, NL;

Ronald Vogels, Linschoten, NL;

Joost A. Kolkman, Maarn, NL;

Robert Heinz Edward Friesen, Wassenaar, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/08 (2006.01); A61K 39/145 (2006.01); C07K 16/10 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1018 (2013.01); C07K 16/08 (2013.01); G01N 33/56983 (2013.01); A61K 39/145 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/526 (2013.01); C07K 2317/62 (2013.01); C07K 2317/64 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); G01N 2333/11 (2013.01); G01N 2800/26 (2013.01);
Abstract

Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.


Find Patent Forward Citations

Loading…